Linked Life Data

10690871

Source:http://linkedlifedata.com/resource/pubmed/id/10690871

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-3-9
pubmed:abstractText
The aim of the present study was to evaluate the prevalence of adrenal suppression and growth retardation in children using moderate doses of budesonide or fluticasone propionate. Seventy-five asthmatic children were randomly divided into three treatment groups: 30 to the fluticasone propionate (FP), 30 to the budesonide (BUD), and 15 to the cromone (CROM) group. FP doses were 500 microg/day during the first 2 months and 200 microg/day thereafter. The respective BUD doses were 800 and 400 microg/day. A low dose ACTH (0.5 microg/1.73 m2) test was performed before treatment and 2, 4, and 6 months later. The test was considered abnormal if the stimulated serum cortisol concentration was more than 2 SD lower than the pretreatment mean (<330 nmol/L). The low dose ACTH test was abnormal after both the high and low steroid doses in 23% of the children. At the 4 month measurement there were more abnormal tests in the BUD (n = 9) than in the FP (n = 5) group (P < 0.05). At that time also the stimulated concentration of serum cortisol was lower in the BUD than in the CROM group (P < 0.01), whereas the difference between the FP and CROM groups was not significant. During the study year the mean decrease in height SD score was 0.23 in the children treated with BUD, 0.03 in the children treated with FP, and 0.09 in the children treated with CROM; the difference between the BUD and FP groups was significant (P < 0.05). In conclusion, the low dose ACTH test revealed mild adrenal suppression in a quarter of the children using moderate doses of inhaled steroids. A FP dose of 200 microg/day caused less adrenal and growth suppression than did a BUD dose of 400 microg/day.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0021-972X
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
652-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10690871-Administration, Inhalation, pubmed-meshheading:10690871-Adolescent, pubmed-meshheading:10690871-Adrenal Glands, pubmed-meshheading:10690871-Adrenocorticotropic Hormone, pubmed-meshheading:10690871-Androstadienes, pubmed-meshheading:10690871-Anti-Asthmatic Agents, pubmed-meshheading:10690871-Anti-Inflammatory Agents, pubmed-meshheading:10690871-Asthma, pubmed-meshheading:10690871-Budesonide, pubmed-meshheading:10690871-Child, pubmed-meshheading:10690871-Child, Preschool, pubmed-meshheading:10690871-Cromolyn Sodium, pubmed-meshheading:10690871-Dose-Response Relationship, Drug, pubmed-meshheading:10690871-Female, pubmed-meshheading:10690871-Growth, pubmed-meshheading:10690871-Humans, pubmed-meshheading:10690871-Hydrocortisone, pubmed-meshheading:10690871-Male, pubmed-meshheading:10690871-Nedocromil
pubmed:year
2000
pubmed:articleTitle
Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids.
pubmed:affiliation
Department of Pediatrics, Kuopio University Hospital, Finland.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't